Majority of younger patients dying of cancer use aggressive interventions in last month of life
the ONA take:
According to a recent study published in JAMA Oncology, researchers at Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center and Kaiser Permanente Southern California have found that more than two-thirds of adolescents and young adults dying as a result of cancer underwent at least one aggressive intervention during the last month of life.
For the study, researchers evaluated the use of intensive care, the emergency room, chemotherapy, and/or hospitalization in the last month of life in 633 patients aged 15 to 39 years who died of cancer between 2001 and 2010.
Results showed that young patients were more than two times as likely as patients 65 and older to receive intensive care and/or use the emergency room during the last month of life. The rate of use of chemotherapy and hospitalization was similar among both age groups. Researchers found that 22% of the adolescents and young adults used intensive care and/or the emergency room in the last month of life, 11% received chemotherapy in the last two weeks of life, and 62% were hospitalized in the last month of life.
The findings suggest that further research is warranted to determine whether younger patients dying of cancer have been adequately supported to make their end-of-life decisions.
More than two-thirds of adolescents and young adults dying as a result of cancer underwent at least one aggressive intervention during the last month of life.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|